Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Pirozzi

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cancers|September 28, 2023
Repurposing Clemastine to Target Glioblastoma Cell StemnessMichael A Sun, Rui Yang, Heng Liu, et al.
Molecular Cancer Research : MCR|February 3, 2017
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor ProgressionChristopher J Pirozzi, Austin B Carpenter, Matthew S Waitkus, et al.
Neuro-Oncology|January 10, 2026
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of TelomeresAlexandrea Brown, Laura M Strickland, Elise N Erman, et al.
Cancer Research|November 4, 2017
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1<sup>R132H</sup>-Induced Metabolic LiabilitiesMatthew S Waitkus, Christopher J Pirozzi, Casey J Moure, et al.
Oncotarget|April 12, 2014
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomasPatrick J Killela, Christopher J Pirozzi, Patrick Healy, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Nature Communications|January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Cancer Research|May 2, 2019
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine StarvationLandon J Hansen, Ran Sun, Rui Yang, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancers|September 28, 2023
Repurposing Clemastine to Target Glioblastoma Cell StemnessMichael A Sun, Rui Yang, Heng Liu, et al.
Molecular Cancer Research : MCR|February 3, 2017
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor ProgressionChristopher J Pirozzi, Austin B Carpenter, Matthew S Waitkus, et al.
Neuro-Oncology|January 10, 2026
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of TelomeresAlexandrea Brown, Laura M Strickland, Elise N Erman, et al.
Cancer Research|November 4, 2017
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1<sup>R132H</sup>-Induced Metabolic LiabilitiesMatthew S Waitkus, Christopher J Pirozzi, Casey J Moure, et al.
Oncotarget|April 12, 2014
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomasPatrick J Killela, Christopher J Pirozzi, Patrick Healy, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Nature Communications|January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Cancer Research|May 2, 2019
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine StarvationLandon J Hansen, Ran Sun, Rui Yang, et al.
Pageof 3